11:39 AM
 | 
Mar 10, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

House dust mite (HDM) sublingual allergy immunotherapy (SLIT) regulatory update

FDA approved a BLA for ALK-Abello’s HDM SLIT to treat HDM-induced rhinitis with or without conjunctivitis. ALK-Abello said the launch of the immunotherapy is “likely looking towards 2018.”...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >